trending Market Intelligence /marketintelligence/en/news-insights/trending/BTK6gMtP7WoZFJsQQ3a_Mg2 content esgSubNav
In This List

Arena Pharmaceuticals heart failure drug APD418 gets fast-track tag from US FDA

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Arena Pharmaceuticals heart failure drug APD418 gets fast-track tag from US FDA

Arena Pharmaceuticals Inc.'s heart failure therapy APD418 received the U.S. Food and Drug Administration's fast-track designation.

The designation gives regulatory priority to treatments that show promise and offers incentives such as more frequent communication with the regulator and the opportunity to apply for accelerated approval and priority review.

San Diego-based Arena's therapy treats the sudden worsening of heart failure symptoms, referred to as decompensated heart failure. APD418 is being tested in an early-stage clinical trial.